García-Leiva J, Gamboa-Domínguez A, Ceron-Lizarraga T, Morales-Espinosa D, Meza-Junco J, Arrieta O

Idioma: Ingles.
Referencias bibliográficas: 21
Paginas: 263-267
Archivo PDF: 155.35 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Schafer DF, Sorrell MF Hepatocellular carcinoma. Lancet 1999; 353: 1252-1257.

2. Yu A, Keeffe EB. Management of hepatocellular carcinoma. Rev Gastrenterol Disord 2003; 3(1): 8-24.

3. Kew MC. Role of cirrhosis in hepatocarcinogenesis. In: Bannasch P, Keppler D, Weber G, (eds) Liver cell carcinoma. Dordrecht: Kluwer Academic Publishers 1989: 37-46.

4. Leung T, Johnson PJ. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001; 28: 514-520.

5. Aguayo A. Patt Yehuda Nonsurgical treatment of hepatocellular carcinoma. Semin Oncol 2001; 28: 503-513.

6. Mondragón-Sanchez R. Tamoxifen and hepatocarcinoma. Rev Gastroenterol Mex 1998; 63: 163-130.

7. Macaigne G, Auriault ML, Boivin JF, Cheaib S, Chayette C, Deplus R. Regression of hepatocellular carcinoma under tamoxifen: report of one case and review of literature. Gastroenterol Clin Biol 2002; 26(12): 1165-7.

8. Jiang SY, Shyu RY, Yeh MY, Jordan VC. Tamoxifen inhibits hepatoma cell growth trough an estrogen receptor independent mechanism. J Hepatol 1995; 23: 712-19.

9. Martínez CFJ, Tomas A, Donoso L, Enriquez J, Guarner C, Balanzo, Martinez NA et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994; 20: 702-06.

10. Farinati F, Salvagnini M, De Maria N, Fornasiero A, Chiaramonte M, Rossaro L. Naccarato R, et al. Unresecable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol 1990; 11: 297-301.

11. Elba S, Giannuzzi V, Misciagna G, Manghisi OG. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ita J Gatroenterol 1994; 26: 66-68.

12. Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L, Vilana R, Rodes J, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind trial in 120 patients. Gastroenterology 1995; 109: 917-922.

13. Riestra S, Rodriguez M, Delgado M, Suarez A, Gonzalez N, de la Mata M, Diaz G, et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol 1998; 26: 200-3.

14. CLIP Group (Cancer of the Liver Italian Programme) Tamoxifen in treatment of hepatocellular carcinoma: a randomized controlled trial. Lancet 1998; 352: 17-20.

15. Lai EC, Choi TK, Chen CH, Mok F, Fan S, Tan E, Wong J. Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil. Cancer 1990; 66(8): 1685-7.

16. Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 1997; 24: 165-170.

17. Liu CL, Fan ST, Ng IO, Lo CM, Pon RT. Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: A prospective randomized study. Am J Gastroenterol 2000; 95: 218-22.

18. Barbare JC, Bouché O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005; 23: 4338-4346.

19. Chow PK, Tai BC, Machin D, Win KM, Johnson PJ. High doses tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002; 36(5): 1221-6.

20. Manesis EK, Giannoulis G, Zoumbuulis P, Vafiadou I, Hadzivannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: randomized controlled trial. Hepatology 1995; 21: 1535-1542.

21. Villa E, Colantoni A, Grottola A, Ferretti I, Buttafoco P, Bertani H, De Maria N, et al. Variant estrogen receptor and their role in liver disease. Mol Cell Endocrinol 2002; 193(1-2): 65-9.